Research Analysts’ Weekly Ratings Changes for Edwards Lifesciences (EW)

Several brokerages have updated their recommendations and price targets on shares of Edwards Lifesciences (NYSE: EW) in the last few weeks:

• 7/28/2026 – Edwards Lifesciences is now covered by UBS Group AG. They set a “buy” rating and a $110.00 price target on the stock.
• 7/24/2026 – Edwards Lifesciences had its “overweight” rating reaffirmed by Piper Sandler. They now have a $101.00 price target on the stock, up from $100.00.
• 7/24/2026 – Edwards Lifesciences had its price target raised by JPMorgan Chase & Co. from $100.00 to $105.00. They now have an “overweight” rating on the stock.
• 7/24/2026 – Edwards Lifesciences was upgraded by Leerink Partners from “market perform” to “outperform”. They now have a $101.00 price target on the stock, up from $87.00.
• 7/21/2026 – Edwards Lifesciences had its “buy” rating reaffirmed by TD Cowen.
• 7/17/2026 – Edwards Lifesciences had its “hold (c)” rating reaffirmed by Weiss Ratings.
• 7/16/2026 – Edwards Lifesciences had its price target raised by Truist Financial Corporation from $90.00 to $95.00. They now have a “hold” rating on the stock.
• 7/15/2026 – Edwards Lifesciences had its price target raised by Mizuho from $100.00 to $105.00. They now have an “outperform” rating on the stock.
• 7/13/2026 – Edwards Lifesciences had its price target raised by Royal Bank Of Canada from $100.00 to $110.00. They now have an “outperform” rating on the stock.
• 7/8/2026 – Edwards Lifesciences had its price target raised by Citigroup Inc. from $101.00 to $110.00. They now have a “buy” rating on the stock.
• 7/6/2026 – Edwards Lifesciences had its “outperform” rating reaffirmed by Evercore Inc. They now have a $100.00 price target on the stock.
• 7/4/2026 – Edwards Lifesciences was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/30/2026 – Edwards Lifesciences had its price target raised by BTIG Research from $100.00 to $110.00. They now have a “buy” rating on the stock.
• 6/16/2026 – Edwards Lifesciences had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $100.00 price target on the stock.

Insider Activity

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 23,145 shares of Edwards Lifesciences stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the completion of the sale, the vice president directly owned 98,611 shares of the company’s stock, valued at $8,521,962.62. The trade was a 19.01% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Andrew M. Dahl sold 568 shares of the company’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the sale, the senior vice president directly owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 26,190 shares of company stock valued at $2,269,697. Corporate insiders own 0.31% of the company’s stock.

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.